- Central European Biotechnology Portal
be visible on the BioBusiness market                  ISSN 2300-0228
Avastin – chance in cancer treatment

Avastin – chance in cancer treatment

Publish date: 2014-08-27

European Commission (EC) approved the bevacizumab (Avastin) as a medication in treating recurrent ovarian cancer resistant to chemotherapy containing platinum. Avastin has to be combined with paclitaxel, topotecan, or pegylated liposomal doxorubicin chemotherapy.

Tags: cancer , Avastin , cancer therapy , ovarian cancer

AURELIA is a study that involves women with recurrence of platinum-resistant ovarian cancer. As a result of the phase 3 study addition of the Avastin to the anticancer therapy have clinical meaning - it extend the progression free survival.

Platinum-resistant ovarian cancer is very dangerous and progressive because it gives the recurrence very fast (mean time without recurrence about 3.4 months). During clinical studies Avastin elongates this time to 6.7 months.

Specialists still do not know why this type of cancer is platinum resistant, for now, there is no effective cure. Avastin registration by European Commission (EC) will enable its usage with combination of paclitaxel, topotecan, or pegylated liposomal doxorubicin and extends the survival rate without cancer progression. Avastin is first biologic drug approved by EC in the treatment of platinum-resistant ovarian cancer.

Ovarian cancer is cancer developed from ovarian cells, that have ability to spread not only to other parts of gynecological system, but also to give metastasis to another parts of the body. In early onset it gives no special symptoms. Among the risk factors are hormone replacement therapy, but from the other hand birth control decrease the risk. It is all about the ovulation, women that ovulate more frequent and without break (therefore those who never had children) are in higher risk. The risk rises also within those that carry a mutations in BRCA1 and BRCA2.

In European Union(EU) are diagnosed about 44 thousands recurrence every year in women with ovarian cancer. Within those patients with initial treatment about 10 000 will show the platinum resistant type of tumor per year. General statistics says that in 2011 more than 7 thousands of women in UK were diagnosed with ovarian cancer, barely 4300 died. Over 2005 – 2009 only 42,9 % survived the ovarian cancer in England. For now it has the highest mortality rate of all gynecological cancers.

Hanna Banasiak



Add comment
2016-04-03 03:16:42 +0200
'After being in relationship with Wilson for seven years,he broke up with me, I did everything possible to bring him back but all was in vain, I wanted him back so much because of the love I have for him, I begged him with everything, I made promises but he refused. I explained my problem to someone online and she suggested that I should contact a spell caster that could help me cast a spell to bring him back but I am the type that don't believed in spell, I had no choice than to try it, I meant a spell caster called Dr Zuma zuk and I email him, and he told me there was no problem that everything will be okay before three days, that my ex will return to me before three days, he cast the spell and surprisingly in the second day, it was around 4pm. My ex called me, I was so surprised, I answered the call and all he said was that he was so sorry for everything that happened, that he wanted me to return to him, that he loves me so much. I was so happy and went to him, that was how we started living together happily again. Since then, I have made promise that anybody I know that have a relationship problem, I would be of help to such person by referring him or her to the only real and powerful spell caster who helped me with my own problem and who is different from all the fake ones out there. Anybody could need the help of the spell caster, his email: or call him +2349055637784 you can email him if you need his assistance in your relationship or anything. CONTACT HIM NOW FOR SOLUTION TO ALL YOUR PROBLEMS'
See also
Researchers at Johns Hopkins University have identified a gene which repressed in tumor cells, puts a halt to c... Read more
Tags: medicine , cancer
Cancer experts from Denmark have found an enzyme that seems to induce cancer senescence.... Read more
Tags: cancer , medicine
On 1 November 2013, Genentech announced that the U.S. Food and Drug Administration (FDA) approved Gazyva (obinu... Read more
Tags: cancer , leukemia , CLL , antibody , Genentech , Roche , chemoterapy